This review has shown evidence that melatonin has a role in the treatment of some primary sleep disorders, namely primary insomnia, DSPS, non-24 hour sleep-wake disorder in people who are blind, and Rapid Eye Movement-Behavioural Disorder
2016
Key concepts
Scholarcy highlights
- This identified all studies that compared the effect of exogenous melatonin and placebo in patients with primary insomnia, delayed sleep phase syndrome, Non 24
- Results from the meta-analyses showed the most convincing evidence for exogenous melatonin use was in reducing sleep onset latency in primary insomnia, delayed sleep phase syndrome, and regulating the sleepwake patterns in blind patients compared with placebo
- The studies included in analysis comprised a total of 1,510 patients, all aged between 18-80 years with either primary insomnia, DSPS, blindness, or Rapid Eye Movement-Behavioural Disorder
- Quantitative analysis of the five eligible randomised controlled trials showed an overall significant reduction in the time to fall asleep between the effect on sleep onset latency for melatonin in patients with primary insomnia compared with placebo
- This review has shown evidence that melatonin has a role in the treatment of some primary sleep disorders, namely primary insomnia, DSPS, non-24 hour sleep-wake disorder in people who are blind, and RBD
- Administered melatonin has been shown to improve sleep onset latency in primary insomnia, DSPS, and to normalise free-running rhythms in people who are blind
Need more features? Save interactive summary cards to your Scholarcy Library.